<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3272">
  <stage>Registered</stage>
  <submitdate>23/08/2011</submitdate>
  <approvaldate>23/08/2011</approvaldate>
  <nctid>NCT01422941</nctid>
  <trial_identification>
    <studytitle>Safety and Performance of the CAVU Medical, Inc. Attune Tubing Study</studytitle>
    <scientifictitle>A PROSPECTIVE, MULTI-CENTER CLINICAL EVALUATION TO ASSESS SAFETY AND PERFORMANCE OF CAVU MEDICAL, INC.'S ATTUNE TUBING WHEN USED WITH NEWLY-IMPLANTED LAPAROSCOPIC ADJUSTABLE GASTRIC BANDS (LAGBs)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TP0271</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - CAVU Attune Device

Experimental: CAVU Attune Device - 


Treatment: devices: CAVU Attune Device
The CAVU Attune device is used with LAGB.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The rate of successful placement and filling of the CAVU Medical Attune device without serious device-related adverse events.</outcome>
      <timepoint>30 Days</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. The subject is at least 18 years of age.

          2. The subject has been informed of the nature of the trial and agrees to its provisions.

          3. The subject has a pre-implantation BMI within the protocol limits.

          4. The subject agrees to the follow-up visit schedule.

          5. The subject is a candidate for a LAGB procedure.

          6. The subject agrees to comply with specified follow-up evaluations.

          7. The subject is willing to fast for 2 hours prior to each adjustment visit.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. The subject is pregnant or is not willing to use an effective method of birth control
             for the duration of the trial.

          2. The subject has a condition that is contraindicated for LAGB procedures.

          3. The subject is currently using weight loss medications or supplements.

          4. The subject has a concurrent terminal medical condition with a life expectancy of less
             than 12 months.

          5. The subject is currently participating in an investigational drug or another medical
             device trial.

          6. The subject had a previous LAGB procedure.

          7. The Investigator believes that the patient has physical or mental conditions that
             would render trial participation inappropriate.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Institute of Weight Control - Baulkham Hills</hospital>
    <hospital>St. George Private Hospital - Kogarah</hospital>
    <postcode>2154 - Baulkham Hills</postcode>
    <postcode>2217 - Kogarah</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cavu Medical, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objectives of this clinical research project are to demonstrate the safety and
      feasibility of CAVU Medical, Inc.'s Attune Device.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01422941</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Anthony Brancatisano, B Appl Sc</name>
      <address>Institute of Weight Control</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>